Lemzoparlimab

来佐利单抗

Report date: 2026/03/27 20:01:50

Base Information

Drug NameLemzoparlimab
Drug Alias NamelemzoparlimabTJ-011133TJC-4ABBV-IMAB-TJC4TJ-1133
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCluster of differentiation 47 inhibitors
TargetsCluster of differentiation 47
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesHematologic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyAustralia +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesI-Mab Biopharma Co LtdAbbvie Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesI-Mab Biopharma Us LtdI-Mab Biopharma Co Ltd
Inactive CompaniesAbbvie Inc
Active IndicationsSolid tumoursHematologic NeoplasmsLymphoma +[4] 
Inactive IndicationsMyelodysplastic SyndromesMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksDrugBank